Oteracil

證據等級: L2 | 預測適應症: 10


## 藥師評估報告

Oteracil:從胃癌到大腸腫瘤

一句話總結

Oteracil 是 S-1 複方的成分之一,原本用於胃癌治療。 TxGNN 模型預測它可能對**大腸腫瘤 (Colonic Neoplasm)** 有效, 目前有 **7 個臨床試驗**和 **10 篇文獻**支持這個方向。

快速總覽

項目 內容
原適應症 胃癌用藥。
預測新適應症 colonic neoplasm、cecum villous adenoma、cecum neuroendocrine tumor G1、lipoma of colon、cecal disease、rectosigmoid junction neoplasm、benign neoplasm of cecum、colonic lymphangioma、colon leiomyoma、cavernous hemangioma of colon
TxGNN 預測分數 99.99%
證據等級 L2
台灣上市 ✓ 已上市
許可證數 8 張
建議決策 Proceed with Guardrails

預測適應症詳細分析

1. colonic neoplasm L1 99.99% 主要分析

為什麼這個預測合理?

目前缺乏詳細的作用機轉資料。根據已知資訊,Oteracil 是 S-1 複方的一部分,其成分在胃癌中的療效已被證實,機轉上可能適用於大腸腫瘤。S-1 包含的 tegafur 是 5-FU 的前驅藥,已知能夠抑制快速分裂的癌細胞中的 DNA 合成,這在大腸腫瘤中可能有效。

</p>

此預測基於藥物的作用機轉,與現有臨床證據方向一致。

臨床試驗

試驗編號階段狀態人數主要發現
NCT00524706PHASE1, PHASE2UNKNOWN42Phase I/II Study of S-1, Oral Leucovorin, and Oxaliplatin Combination Therapy (S...
NCT02618356PHASE2UNKNOWN82A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment fo...
NCT00974389PHASE2UNKNOWN40Phase II Study of Combination Chemotherapy With S-1 Plus Avastin in Unresectable...
NCT01918852PHASE3COMPLETED161S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Canc...
NCT03448549PHASE3UNKNOWN1191A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S...
NCT06255379PHASE2NOT_YET_RECRUITING52An Open, Single-arm, Multicenter, Prospective Phase II Study of Fuquinitinib Com...
NCT00660894PHASE3COMPLETED1535Randomized Phase III Study of UFT+Leucovorin vs. TS-1 as Adjuvant Treatment for ...
NCT02216149PHASE2TERMINATED20Effects of S-1 and Capecitabine in Combination With Oxaliplatin on the Coronary ...

相關文獻

PMID年份類型期刊主要發現
252090932014ArticleClinical colorectal cancerAdaptation of international guidelines for metastatic colorectal cancer: an asia...
284141952017ArticleEuropean journal of dermatologTegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal...
205005142010ArticleCancer scienceCharacterization of a novel lymph node metastasis model from human colonic cance...
329367222021ArticleJournal of oncology pharmacy pHypertriglyceridemia induced by S-1: A novel case report and review of the liter...
268051062015ArticleGan to kagaku ryoho. Cancer & [A Successful Case of Treatment of Colonic Metastasis and Peritoneal Recurrence ...
174964612007ArticleGan to kagaku ryoho. Cancer & [Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem ...
319171222020ArticleClinical colorectal cancerS-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuva...
294910682018ArticleAnticancer researchPre-exposure to Fluorouracil Increased Trifluridine Incorporation and Enhanced i...
269769712016ArticleAnticancer researchGenome-wide DNA Copy-number Analysis in ACTS-CC Trial of Adjuvant Chemotherapy f...
128338572003ArticleNihon Shokakibyo Gakkai zasshi[Recent advances in chemotherapy for digestive cancers with special references t...
251320362014ArticleGan to kagaku ryoho. Cancer & [A case of disseminated carcinomatosis of the bone marrow with disseminated intr...
270569962016ArticleAnnals of oncology : official A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy f...
408409132025ArticleGan to kagaku ryoho. Cancer & [A Case of Long-Term Complete Remission with Solitary Metastasis Following Surge...
260364662015ArticleBMC cancerRandomized phase II study of S-1 dosing schedule for resected colorectal cancer.
321891562020ArticleInternational journal of cliniEfficacy and feasibility of S-1 plus oxaliplatin (C-SOX) for treating patients w...
249422772014ArticleAnnals of oncology : official S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III ...
233209012013ArticleTrialsOptimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: s...
218754732011ArticleZhonghua zhong liu za zhi [Chi[Efficacy and side effects of combination therapy of oxaliplatin and S-1 for col...
108972092000ArticleGan to kagaku ryoho. Cancer & [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
260451192015ArticleTumoriLong-term survival in metastasized leiomyosarcoma: a case report and review of t...
</details>
2. cecum villous adenoma L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果,需進一步驗證。
3. cecum neuroendocrine tumor G1 L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果,需進一步驗證。
4. lipoma of colon L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果,需進一步驗證。
5. cecal disease L4 99.98%

相關文獻(9 篇)

PMID年份類型期刊主要發現
390247932024ArticleJournal of pharmaceutical and Amelioration of hyperuricemia by cordycepin and Cordyceps militaris aqueous extr...
259182662015ArticleHinyokika kiyo. Acta urologica[Vesico-appendiceal fistula caused by appendiceal cancer: a case report].
223336482012ArticleGan to kagaku ryoho. Cancer & [A case of cecal cancer with abdominal wall abscess].
306923842018ArticleGan to kagaku ryoho. Cancer & [A Case of Complete Response to Computed Tomography-Guided Celiac Plexus Neuroly...
240185982013ArticleJOP : Journal of the pancreasSynchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 ...
174313532007ArticleGan to kagaku ryoho. Cancer & [Successful low-dose TS-1 administration in an elderly colon cancer patient with...
166121662006ArticleGan to kagaku ryoho. Cancer & [A case of advanced colon cancer with metastases to both para-aortic lymph nodes...
293623082018ArticleGan to kagaku ryoho. Cancer & [An Elderly Patient with Metastatic Colon Cancer Achieved Long-Term Survival Fol...
241898222013ArticleNihon Shokakibyo Gakkai zasshi[A case of advanced signet ring cell carcinoma of the appendix that responded to...
6. rectosigmoid junction neoplasm L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果,需進一步驗證。
7. benign neoplasm of cecum L4 99.98%

相關文獻(6 篇)

PMID年份類型期刊主要發現
109979342000ArticleDrug metabolism and dispositioTissue distribution and biotransformation of potassium oxonate after oral admini...
240185982013ArticleJOP : Journal of the pancreasSynchronous triple cancers of the pancreas, stomach, and cecum treated with S-1 ...
222024312011ArticleGan to kagaku ryoho. Cancer & [A long-term survival case in advanced mucinous cystadenocarcinoma of the append...
223336482012ArticleGan to kagaku ryoho. Cancer & [A case of cecal cancer with abdominal wall abscess].
261992492015ArticleGan to kagaku ryoho. Cancer & [Clinical Response of Metastatic Colon Cancer to Chemotherapy with S-1 and Oxali...
174313532007ArticleGan to kagaku ryoho. Cancer & [Successful low-dose TS-1 administration in an elderly colon cancer patient with...
8. colonic lymphangioma L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果,需進一步驗證。
9. colon leiomyoma L4 99.98%

相關文獻(1 篇)

PMID年份類型期刊主要發現
403223912025ArticleCureusTorsion of Metastatic Ovarian Tumor Originating From Sigmoid Colon Cancer.
10. cavernous hemangioma of colon L5 99.98%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果,需進一步驗證。
## 台灣上市資訊 | 許可證號 | 品名 | 劑型 | 核准適應症 | |---------|------|------|-----------| | 衛部藥製字第061956號 | "杏輝"氮尿嘧啶酸鉀鹽 | (粉) | 胃癌用藥。 | | 衛部藥製字第058552號 | "台耀"歐特拉西兒 | 粉劑 | 胃癌用藥。 | | 衛署藥輸字第025243號 | 愛斯萬膠囊20毫克 | 膠囊劑 | 胃癌、胰臟癌、大腸直腸癌、非小細胞肺癌、膽道癌、早期乳癌 | ## 細胞毒性 | 項目 | 內容 | |------|------| | 細胞毒性分類 | 傳統細胞毒性藥物(Fluoropyrimidine 類) | | 骨髓抑制風險 | 中度 | | 致吐性分級 | 低至中度 | | 監測項目 | CBC(含分類)、肝腎功能、電解質 | | 處置防護 | 需依細胞毒性藥物處置規範操作 | ## 安全性考量 安全性資訊請參考原廠仿單。 ## 結論與下一步 **決策:Proceed with Guardrails** **理由:** 有多個 Phase 2/3 臨床試驗支持 S-1 用於結直腸癌的療效,且 S-1 複方已在台灣取得大腸直腸癌適應症,證據充分。 **若要推進需要:** - 詳細的藥物作用機轉資料(MOA) - 特定族群的安全性監測計畫 --- ## 相關藥物報告 - [Prednisone](/drugs/prednisone/) - 證據等級 L2 - [Regorafenib](/drugs/regorafenib/) - 證據等級 L2 - [Isosorbide Dinitrate](/drugs/isosorbide_dinitrate/) - 證據等級 L2 - [Dronedarone](/drugs/dronedarone/) - 證據等級 L2 - [Carboplatin](/drugs/carboplatin/) - 證據等級 L2 ---
用 AI 幫我深入分析

想進一步了解這個藥物的老藥新用潛力嗎?點擊下方按鈕,直接開啟 AI 助手進行分析。

Claude:點擊後會複製提問並開啟新視窗,請按 Ctrl+V(Mac: Cmd+V)貼上
ChatGPT:點擊後直接開啟並自動帶入提問

## 引用本報告 如需引用本報告,請使用以下格式: **APA 格式:** ``` TwTxGNN. (2026). Oteracil老藥新用驗證報告. https://twtxgnn.yao.care/drugs/oteracil/ ``` **BibTeX 格式:** ```bibtex @misc{twtxgnn_oteracil, title = {Oteracil老藥新用驗證報告}, author = {TwTxGNN Team}, year = {2026}, url = {https://twtxgnn.yao.care/drugs/oteracil/} } ``` ---
免責聲明
本報告僅供學術研究參考,不構成醫療建議。藥物使用請遵循醫師指示,切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。

最後審核:2026-02-20 | 審核者:TwTxGNN Research Team

討論與回饋

歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。


回到頂部

Copyright © 2026 Yao.Care. 本報告僅供研究參考,不構成醫療建議。

This site uses Just the Docs, a documentation theme for Jekyll.